Table 3:
Cox proportional hazard regression model. Multivariable adjusteda hazard ratios (HR) and associated 95% confidence intervals (95% CI) of late effect among 2-year adolescent and young adult cutaneous melanoma survivors, California, 1996-2012
| Variable | Hematologic Disorders HR (95% CI) |
Cardiac Disease HR (95% CI) |
Diabetes Mellitus HR (95% CI) |
Endocrine Disorders HR (95% CI) |
Lymphedema HR (95% CI) |
VTE HR (95% CI) |
Autoimmune Disorders HR (95% CI) |
Infection/Sepsis HR (95% CI) |
Subsequent Melanoma HR (95% CI) |
Subsequent Cancer(Otherb) HR (95% CI) |
|---|---|---|---|---|---|---|---|---|---|---|
| Age | ||||||||||
| 15-24 | Referent | Referent | Referent | Referent | Referent | Referent | Referent | Referent | Referent | Referent |
| 25-29 | 0.85 (0.68, 1.05) |
0.82 (0.61, 1.10) |
0.90 (0.68, 1.18) |
0.88 (0.66, 1.18) |
0.94 (0.72, 1.21) |
0.81 (0.62, 1.06) |
0.84 (0.62, 1.13) |
0.87 (0.68, 1.11) |
0.98 (0.75, 1.28) |
0.83 (0.62, 1.10) |
| 30-34 | 0.87 (0.71, 1.07) |
0.95 (0.73, 1.24) |
1.02 (0.80, 1.31) |
1.11 (0.86, 1.45) |
1.28 (1.02, 1.60) |
0.99 (0.78, 1.26) |
0.98 (0.75, 1.29) |
0.94 (0.75, 1.17) |
1.17 (0.92, 1.48) |
1.04 (0.82, 1.33 |
| 35-39 | 1.01 (0.84, 1.21) |
1.15 (0.90, 1.46) |
1.19 (0.95, 1.49) |
1.35 (1.06, 1.72) |
1.67 (1.36, 2.06) |
1.17 (0.94, 1.46) |
1.17 (0.92, 1.50) |
1.12 (0.92, 1.37) |
1.33 (1.07, 1.65) |
1.27 (1.02, 1.59) |
| Race/ethnicity | ||||||||||
| NH White | Referent | Referent | Referent | Referent | Referent | Referent | Referent | Referent | Referent | Referent |
| Hispanic | 0.88 (0.70, 1.10) |
0.89 (0.67, 1.19) |
0.97 (0.76, 1.26) |
0.96 (0.73, 1.26) |
0.97 (0.78, 1.22) |
0.99 (0.77, 1.28) |
0.90 (0.68, 1.21) |
0.90 (0.71, 1.15) |
0.82 (0.63, 1.06) |
1.03 (0.81, 1.33) |
| Other/unknownc | 0.79 (0.60, 1.03) |
0.70 (0.48, 1.02) |
0.78 (0.56, 1.07) |
0.77 (0.54, 1.08) |
0.78 (0.59, 1.02) |
0.77 (0.55, 1.06) |
0.76 (0.52, 1.09) |
0.91 (0.69, 1.19) |
0.62 (0.45, 0.86) |
0.58 (0.41, 0.83) |
| Sex | ||||||||||
| Female | Referent | Referent | Referent | Referent | Referent | Referent | Referent | Referent | Referent | Referent |
| Male | 1.17 (1.03, 1.33) |
1.73 (1.47, 2.03) |
1.27 (1.10, 1.48) |
1.67 (1.43, 1.95) |
1.56 (1.37, 1.77) |
1.44 (1.25, 1.67) |
1.80 (1.54, 2.12) |
1.59 (1.39, 1.82) |
1.53 (1.33, 1.75) |
1.51 (1.31, 1.74) |
| Neighborhood SES | ||||||||||
| High SES | Referent | Referent | Referent | Referent | Referent | Referent | Referent | Referent | Referent | Referent |
| Low SES | 1.29 (1.14, 1.47) |
1.31 (1.11, 1.54) |
1.27 (1.09, 1.47) |
1.38 (1.18, 1.61) |
1.36 (1.20, 1.55) |
1.33 (1.15, 1.54) |
1.29 (1.10, 1.52) |
1.28 (1.12, 1.46) |
1.08 (0.94, 1.24) |
1.14 (0.99, 1.32) |
| Health insurance | ||||||||||
| Private | Referent | Referent | Referent | Referent | Referent | Referent | Referent | Referent | Referent | Referent |
| Public/none | 2.30 (1.95, 2.72) |
2.87 (2.36, 3.49) |
2.60 (2.16, 3.13) |
2.72 (2.25, 3.29) |
2.22 (1.87, 2.63) |
2.68 (2.23, 3.22) |
2.81 (2.31, 3.42) |
2.69 (2.27, 3.19) |
2.41 (2.01, 2.88) |
2.34 (1.94, 2.82) |
| Unknown | 0.88 (0.69, 1.13) |
0.73 (0.51, 1.05) |
0.78 (0.57, 1.06) |
0.80 (0.58, 1.10) |
0.82 (0.64, 1.05) |
0.75 (0.55, 1.03) |
0.67 (0.46, 0.97) |
0.76 (0.58, 1.00) |
0.70 (0.52, 0.95) |
0.84 (0.63, 1.12) |
| Surgery | ||||||||||
| Yes | Referent | Referent | Referent | Referent | Referent | Referent | Referent | Referent | Referent | Referent |
| No/unknown | 1.04 (0.67, 1.61) |
0.56 (0.26, 1.19) |
0.73 (0.40, 1.33) |
0.78 (0.43, 1.44) |
0.78 (0.46, 1.30) |
0.93 (0.55, 1.60) |
0.56 (0.26, 1.19) |
0.79 (0.46, 1.34) |
0.81 (0.47, 1.42) |
0.97 (0.57, 1.66) |
NH= Non-Hispanic; SES= socioeconomic status; VTE= venous thromboembolism
a
Models adjusted for all variables in the table and stratified by stage at diagnosis and year of diagnosis
b
Includes all subsequent primary cancers, except subsequent melanomas
c
Other/unknown race/ethnicity includes non-Hispanic Black, non-Hispanic Asian/Pacific Islander and other/unknown